Oxford BioDynamics Plc (LON:OBD – Get Free Report) traded up 18.3% on Wednesday . The company traded as high as GBX 0.20 and last traded at GBX 0.20. 1,739,901 shares were traded during mid-day trading, a decline of 88% from the average session volume of 15,004,250 shares. The stock had previously closed at GBX 0.17.
Oxford BioDynamics Price Performance
The company has a debt-to-equity ratio of 457.97, a quick ratio of 2.80 and a current ratio of 0.88. The business has a 50 day moving average price of GBX 0.20 and a 200-day moving average price of GBX 0.24. The company has a market capitalization of £8.58 million, a price-to-earnings ratio of -0.25 and a beta of 0.42.
Oxford BioDynamics Company Profile
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Read More
- Five stocks we like better than Oxford BioDynamics
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
